CARPHENAZINE

US Previously Marketed

Details

Stereochemistry	ACHIRAL
Molecular Formula	C24H31N3O2S
Molecular Weight	425.587
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCC(=O)C1=CC2=C(SC3=C(C=CC=C3)N2CCCN4CCN(CCO)CC4)C=C1

InChI

InChIKey=XZSMZRXAEFNJCU-UHFFFAOYSA-N

InChI=1S/C24H31N3O2S/c1-2-22(29)19-8-9-24-21(18-19)27(20-6-3-4-7-23(20)30-24)11-5-10-25-12-14-26(15-13-25)16-17-28/h3-4,6-9,18,28H,2,5,10-17H2,1H3

HIDE SMILES / InChI

Molecular Formula	C24H31N3O2S
Molecular Weight	425.587
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.tabletwise.com/us/proketazine-tablet
Curator's Comment: description was created based on several sources, including: http://edudrugs.com/P/Proketazine/more.html | https://en.wikipedia.org/wiki/Carfenazine | https://www.ncbi.nlm.nih.gov/pubmed/14267601

Carfenazine (brand name Proketazine) is an antipsychotic and tranquilizer of the phenothiazine group. It is used in the treatment of acute or chronic schizophrenic reactions in hospitalized patients. Proketazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis. The following is a list of possible side effects that may occur from all constituting ingredients of Proketazine: akathisia, tardive dyskinesia, extrapyramidal symptoms, allergic purpura.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Dopamine D1 receptor 101 Target ID: CHEMBL2056 Sources: https://www.drugbank.ca/drugs/DB01038 \| http://edudrugs.com/P/Proketazine/more.html	Antagonist 2778
Dopamine D2 receptor 297 Target ID: CHEMBL217 Sources: https://www.drugbank.ca/drugs/DB01038 \| http://edudrugs.com/P/Proketazine/more.html	Antagonist 2778

Conditions

Condition	Modality	Targets	Highest Phase	Product
Schizophrenia 298 Sources: http://www.tabletwise.com/us/proketazine-tablet https://www.ncbi.nlm.nih.gov/pubmed/13706536 https://www.ncbi.nlm.nih.gov/pubmed/14218188	Primary		Approved 8429	PROKETAZINE Approved Use Used in the treatment of acute or chronic schizophrenic reactions in hospitalized patients.

Doses

Dose	Population	Adverse events
100 mg 4 times / day steady, oral Dose: 100 mg, 4 times / day Route: oral Route: steady Dose: 100 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/14286057/	unhealthy, 18 - 60 years n = 28 Health Status: unhealthy Condition: acutely psychotic Age Group: 18 - 60 years Sex: F Population Size: 28 Sources: https://pubmed.ncbi.nlm.nih.gov/14286057/	Disc. AE: Skin rash... Other AEs: Faintness... AEs leading to discontinuation/dose reduction: Skin rash (grade 4, 1 patient) Other AEs: Faintness (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/14286057/

AEs

AE	Significance	Dose	Population
Faintness	1 patient	100 mg 4 times / day steady, oral Dose: 100 mg, 4 times / day Route: oral Route: steady Dose: 100 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/14286057/	unhealthy, 18 - 60 years n = 28 Health Status: unhealthy Condition: acutely psychotic Age Group: 18 - 60 years Sex: F Population Size: 28 Sources: https://pubmed.ncbi.nlm.nih.gov/14286057/
Skin rash	grade 4, 1 patient Disc. AE	100 mg 4 times / day steady, oral Dose: 100 mg, 4 times / day Route: oral Route: steady Dose: 100 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/14286057/	unhealthy, 18 - 60 years n = 28 Health Status: unhealthy Condition: acutely psychotic Age Group: 18 - 60 years Sex: F Population Size: 28 Sources: https://pubmed.ncbi.nlm.nih.gov/14286057/

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:51235	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:51235
ZINC	ZINC000064624931	http://zinc15.docking.org/substances/ZINC000064624931

PubMed

Title	Date	PubMed

Patents

Sample Use Guides

In Vivo Use Guide

First week, 25 mg. t.i.d.; second week, 50 mg. t.i.d.; third week, 75 mg. t.i.d.; fourth week, 100 mg. t.i.d.; fifth week and thereafter, 100 mg. q.i.d.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Sat Dec 16 16:49:51 GMT 2023` Edited by `admin` on `Sat Dec 16 16:49:51 GMT 2023`
Record UNII	CLY16Y8Z7E
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CARPHENAZINE

Common Name

English

CARPHENAZINE [MI]

Common Name

English

CARFENAZINE

Official Name

English

carfenazine [INN]

Common Name

English

Carfenazine [WHO-DD]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29710